<p>/PRNewswire/ -- Generate Biomedicines, Inc. (納斯達克: GENB)（&#34;Generate&#34;），是一家處於臨牀階段的生成生物學公司，正在引領生物技術和藥物設計與開發中的人工智能革命，今天宣佈其首次公開募股的定價為 2500 萬股普通股，每股公開發行價格為 16.00 美元。預計此次發行的總收益為 4 億美元，未扣除承銷折扣和佣金以及 Generate 需支付的估計發行費用。此外，Generate 已授予承銷商一個 30 天的選擇權，以初始公開發行價格購買最多 375 萬股，扣除承銷折扣和佣金。所有股份均由 Generate 提供。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg"/></p>
<p>Generate 的普通股預計將於 2026 年 2 月 27 日在納斯達克全球精選市場開始交易，股票代碼為&#34;GENB&#34;。此次發行預計將於 2026 年 3 月 2 日完成，具體取決於慣例的交割條件。</p>
<p>高盛證券公司和摩根士丹利擔任此次發行的聯合主承銷商。Piper Sandler、Guggenheim Securities 和 Cantor 擔任此次發行的承銷商。</p>
<p>與這些證券相關的註冊聲明已提交，並於 2026 年 2 月 26 日獲得美國證券交易委員會的有效聲明。此次發行僅通過招股説明書進行。最終招股説明書的副本在可用時可從高盛證券公司獲取，聯繫人：招股説明書部門，地址：200 West Street, New York, NY 10282，電話：(866) 471-2526，傳真：212 902-9316，或通過電子郵件：prospectus-ny@ny.email.gs.com；摩根士丹利，聯繫人：招股説明書部門，地址：180 Varick Street, 2nd Floor, New York, NY 10014；Piper Sandler &amp; Co.，聯繫人：招股説明書部門，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，電話：(800) 747-3924，或通過電子郵件：prospectus@psc.com；Guggenheim Securities, LLC，聯繫人：股權承銷部門，地址：330 Madison Avenue, 8th Floor, New York, NY 10017，電話：(212) 518-9544，或通過電子郵件：GSEquityProspectusDelivery@guggenheimpartners.com；Cantor Fitzgerald &amp; Co.，聯繫人：資本市場，地址：110 East 59th Street, 6th Floor, New York, New York 10022，或通過電子郵件：prospectus@cantor.com。</p>
<p>本新聞稿不構成出售任何證券的要約，或購買任何證券的要約邀請，也不應在任何州或司法管轄區內進行這些證券的銷售，若在該州或司法管轄區內的證券法下，此類要約、邀請或銷售是非法的，需在註冊或資格確認之前。</p>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>本新聞稿包含某些披露，包含&#34;前瞻性聲明&#34;，包括但不限於，關於 Generate 對其股票在納斯達克全球精選市場開始交易的預期、發行的完成和交割時間以及預計的發行總收益的聲明。前瞻性聲明基於 Generate 當前的預期，並受到固有的不確定性、風險和假設的影響，這些因素難以預測。可能導致實際結果與預期不同的因素包括但不限於與市場條件、滿足慣例交割條件和發行完成相關的風險和不確定性，以及製藥產品開發和臨牀試驗中固有的風險。這些及其他風險和不確定性在提交給證券交易委員會的註冊聲明的&#34;風險因素&#34;部分中有更全面的描述。本公告中包含的前瞻性聲明截至本日期作出，Generate 不承擔更新該信息的義務，除非適用法律要求。讀者不應在本新聞稿發佈後依賴其中的信息為當前或準確。</p>
<p><strong>Generate 聯繫方式</strong></p>
<p>梅根·麥克勞克林</p>
<p>pr@generatebiomedicines.com</p>
<p>來源：Generate:Biomedicines</p>

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

醫藥突破 ETF - ALPS

2 倍做空納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

<p>Generate Biomedicines, Inc. 宣佈其首次公開募股（IPO）定價為每股 16.00 美元，共計 2500 萬股，目標總收益為 4 億美元。該股票將於 2026 年 2 月 27 日在納斯達克交易，股票代碼為 "GENB"，預計募股將在 2026 年 3 月 2 日結束。高盛和摩根士丹利是此次募股的主承銷商。公司已向美國證券交易委員會（SEC）提交了註冊聲明，募股需遵循慣例的成交條件</p>

<p>, /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) (&#34;Generate&#34;), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds from the offering are expected to be $400 million, before underwriting discounts and commissions and estimated offering expenses payable by Generate. In addition, Generate has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares at the initial public offering price, less underwriting discounts and commissions. All shares are being offered by Generate.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Generate Biomedicines, Inc. (納斯達克: GENB)（&#34;Generate&#34;），是一家處於臨牀階段的生成生物學公司，正在引領生物技術和藥物設計與開發中的人工智能革命，今天宣佈其首次公開募股的定價為 2500 萬股普通股，每股公開發行價格為 16.00 美元。預計此次發行的總收益為 4 億美元，未扣除承銷折扣和佣金以及 Generate 需支付的估計發行費用。此外，Generate 已授予承銷商一個 30 天的選擇權，以初始公開發行價格購買最多 375 萬股，扣除承銷折扣和佣金。所有股份均由 Generate 提供。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg"/></p>
<p>Generate's common stock is expected to begin trading on the Nasdaq Global Select Market on February 27, 2026, under the ticker symbol &#34;GENB.&#34; The offering is expected to close on March 2, 2026, subject to customary closing conditions.</p>
<div class="lb-trans"><p>Generate 的普通股預計將於 2026 年 2 月 27 日在納斯達克全球精選市場開始交易，股票代碼為&#34;GENB&#34;。此次發行預計將於 2026 年 3 月 2 日完成，具體取決於慣例的交割條件。</p>
</div><p>Goldman Sachs &amp; Co. LLC and Morgan Stanley are acting as joint lead book-running managers for the offering. Piper Sandler, Guggenheim Securities, and Cantor are acting as book-running managers for the offering.</p>
<div class="lb-trans"><p>高盛證券公司和摩根士丹利擔任此次發行的聯合主承銷商。Piper Sandler、Guggenheim Securities 和 Cantor 擔任此次發行的承銷商。</p>
</div><p>A registration statement relating to these securities has been filed and was declared effective by the U.S. Securities and Exchange Commission on February 26, 2026. This offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, via fax: 212 902-9316, or via email: prospectus-ny@ny.email.gs.com; Morgan Stanley &amp; Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Piper Sandler &amp; Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or via email at prospectus@psc.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com; and Cantor Fitzgerald &amp; Co., Attention: Capital Markets, at 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.</p>
<div class="lb-trans"><p>與這些證券相關的註冊聲明已提交，並於 2026 年 2 月 26 日獲得美國證券交易委員會的有效聲明。此次發行僅通過招股説明書進行。最終招股説明書的副本在可用時可從高盛證券公司獲取，聯繫人：招股説明書部門，地址：200 West Street, New York, NY 10282，電話：(866) 471-2526，傳真：212 902-9316，或通過電子郵件：prospectus-ny@ny.email.gs.com；摩根士丹利，聯繫人：招股説明書部門，地址：180 Varick Street, 2nd Floor, New York, NY 10014；Piper Sandler &amp; Co.，聯繫人：招股説明書部門，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，電話：(800) 747-3924，或通過電子郵件：prospectus@psc.com；Guggenheim Securities, LLC，聯繫人：股權承銷部門，地址：330 Madison Avenue, 8th Floor, New York, NY 10017，電話：(212) 518-9544，或通過電子郵件：GSEquityProspectusDelivery@guggenheimpartners.com；Cantor Fitzgerald &amp; Co.，聯繫人：資本市場，地址：110 East 59th Street, 6th Floor, New York, New York 10022，或通過電子郵件：prospectus@cantor.com。</p>
</div><p>This news release does not constitute an offer to sell, or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售任何證券的要約，或購買任何證券的要約邀請，也不應在任何州或司法管轄區內進行這些證券的銷售，若在該州或司法管轄區內的證券法下，此類要約、邀請或銷售是非法的，需在註冊或資格確認之前。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>This press release includes certain disclosures that contain &#34;forward-looking statements,&#34; including, without limitation, statements regarding Generate's expectations regarding the commencement of trading of its shares on the Nasdaq Global Select Market, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are based on Generate's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to market conditions, the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in pharmaceutical product development and clinical trials. These and other risks and uncertainties are described more fully in the &#34;Risk Factors&#34; section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Generate undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this press release as current or accurate after its publication date.</p>
<div class="lb-trans"><p>本新聞稿包含某些披露，包含&#34;前瞻性聲明&#34;，包括但不限於，關於 Generate 對其股票在納斯達克全球精選市場開始交易的預期、發行的完成和交割時間以及預計的發行總收益的聲明。前瞻性聲明基於 Generate 當前的預期，並受到固有的不確定性、風險和假設的影響，這些因素難以預測。可能導致實際結果與預期不同的因素包括但不限於與市場條件、滿足慣例交割條件和發行完成相關的風險和不確定性，以及製藥產品開發和臨牀試驗中固有的風險。這些及其他風險和不確定性在提交給證券交易委員會的註冊聲明的&#34;風險因素&#34;部分中有更全面的描述。本公告中包含的前瞻性聲明截至本日期作出，Generate 不承擔更新該信息的義務，除非適用法律要求。讀者不應在本新聞稿發佈後依賴其中的信息為當前或準確。</p>
</div><p><strong>Generate Contact</strong></p>
<div class="lb-trans"><p><strong>Generate 聯繫方式</strong></p>
</div><p>Megan McLaughlin</p>
<div class="lb-trans"><p>梅根·麥克勞克林</p>
</div><p>pr@generatebiomedicines.com</p>
<div class="lb-trans"><p>pr@generatebiomedicines.com</p>
</div><p>SOURCE Generate:Biomedicines</p>
<div class="lb-trans"><p>來源：Generate:Biomedicines</p>
</div>

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering | GENB Stock News

StockTitan

Generate Biomedicines, Inc. 宣佈首次公開募股的定價 | GENB 股票新聞